Compare Repligen Corporation Common Stock (RGEN) vs Valley National Bancorp Common Stock (VLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Valley National Bancorp Common Stock — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Valley National Bancorp Common Stock trades at $12.39 (market cap $6.92B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Valley National Bancorp Common Stock pays a 3.51% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Valley National Bancorp Common Stock for 6 Days on average.
| RGEN | VLY | |
|---|---|---|
Market Cap | $11.14B | $6.92B |
Volume | 1,259,263 | 6,202,090 |
Sector | Health | Financials |
52-Week High | $194.57 | $15.19 |
52-Week Low | $102.87 | $9.72 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.02B | $9.43B |
Dividend Yield | — | 3.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Valley National Bancorp (VLY) trades at $12.53, down 0.87% with a bearish technical outlook. The stock shows strong fundamentals with a P/E of 10.61 and P/B of 0.91, indicating potential undervaluation. Recent earnings show mixed results with Q2 2026 missing estimates, but revenue growth remains solid at $2.2B for 2026. The company is actively expanding through acquisitions including Bluevine and Providence Financial to strengthen its deposit base and Chicago market presence.
Analyst consensus remains bullish with 62% buy ratings and a $16.50 price target, suggesting 32% upside potential. Key risks include integration challenges from recent acquisitions and higher operating expenses impacting margins. The upcoming Q3 2026 earnings report on October 22 will be crucial for validating growth trajectory amid current bearish technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Valley National Bancorp Common Stock
Valley National Bancorp is a financial holding company whose main subsidiary is Valley National Bank. It provides commercial, retail, trust, and investment services across several U.S. states.
Read more on VLY →
